Previous studies have shown that bornyl acetate (BA), a key monoterpenoid in PNO, exhibits antitumor activity in liver cancer and breast cancer models by inhibiting proliferation and angiogenesis through inhibition of PI3K/AKT and MAPK/ERK pathways (Chen et al., 2015; Ren et al., 2018). This evidence concerns the gene AKT1 and breast cancer.